Octreotide and lanreotide decrease ovarian ischemia-reperfusion injury in rats by improving oxidative and nitrosative stress

J Obstet Gynaecol Res. 2020 Oct;46(10):2050-2058. doi: 10.1111/jog.14379. Epub 2020 Aug 3.

Abstract

Aim: To investigate the protective effect of octreotide and lanreotide on ovarian damage in experimental ovarian ischemia-reperfusion injury.

Methods: Fifty-six rats were separated into seven groups; group 1: sham group, group 2: surgical control group with 3-h torsion and detorsion, group 3: 0.02 mg/kg s.c. octreotide 30 min before 3-h torsion, group 4; octreotide just after detorsion for 7 days, group 5: octreotide 30 min before torsion and just after detorsion for 7 days, group 6: single time 20 mg/kg s.c. lanreotide before torsion, group 7: single time lanreotide just after detorsion.

Results: All histopathological scores except congestion were significantly lower in group 1 than other groups. In addition, hemorrhage (group 2 vs 4: P < 0.05), degeneration (group 2 vs 4: P < 0.05, group 2 vs 5: P < 0.01 and group 2 vs 6: P < 0.05) and total damage score (group 2 vs 4: P < 0.05, group 2 vs 5: P < 0.05, group 2 vs 6: P < 0.05 and group 2 vs 7: P < 0.05) were significantly lower than other groups. Moreover, ovarian tissue total oxidant status and oxidative stress index levels were significantly decreased in groups 5 (both P < 0.05) and 7 (both P < 0.05) when compared to group 2. Furthermore, tissue levels of peroxynitrite were significantly higher in group 2 than groups 1, 3 and 5 (all P < 0.05).

Conclusions: Octreotide and lanreotide have a protective role against ischemia-reperfusion damage in rat torsion detorsion model by improving histopathological and biochemical findings including tissue levels of total oxidant status, oxidative stress index and peroxynitrite.

Keywords: ischemia-reperfusion injury; lanreotide; octreotide; oxidative stress; peroxynitrite; rat ovarian torsion.

MeSH terms

  • Animals
  • Female
  • Humans
  • Octreotide / pharmacology
  • Octreotide / therapeutic use
  • Ovarian Diseases*
  • Oxidative Stress
  • Peptides, Cyclic
  • Rats
  • Reperfusion Injury* / drug therapy
  • Reperfusion Injury* / prevention & control
  • Somatostatin / analogs & derivatives

Substances

  • Peptides, Cyclic
  • lanreotide
  • Somatostatin
  • Octreotide